Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 300Carcinoma, Non-Small-Cell Lung 262Neoplasms 242Prostatic Neoplasms 204Colorectal Neoplasms 187Lung Neoplasms 145Multiple Myeloma 141Neoplasm Metastasis 126Ovarian Neoplasms 123Leukemia, Myeloid, Acute 115Pancreatic Neoplasms 109Melanoma 96Squamous Cell Carcinoma of Head and Neck 93Recurrence 80Endometrial Neoplasms 78Carcinoma, Renal Cell 76Lymphoma, Non-Hodgkin 74Lymphoma 70Stomach Neoplasms 69Precursor Cell Lymphoblastic Leukemia-Lymphoma 69Carcinoma, Hepatocellular 67Glioblastoma 66Brain Neoplasms 64Sarcoma 62Glioma 62Uterine Cervical Neoplasms 59Head and Neck Neoplasms 59Triple Negative Breast Neoplasms 57Leukemia, Lymphocytic, Chronic, B-Cell 54Urinary Bladder Neoplasms 51

Interventions

darolutamide 1Rifampin 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Refractory or Relapsed Solid Tumors × 30 days × Clear all
NCT07620041 2026-06-02

QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction

Qilu Pharmaceutical Co., Ltd.

Phase 1 Not yet recruiting
48 enrolled
Other solid neoplasm

Refractory or Relapsed Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡